Clinical Trial Detail

NCT ID NCT04068753
Title Niraparib in Combination With TSR-042 in Patients With Recurrent or Progressive Cervix Cancer (STAR)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors University of Oklahoma
Indications

cervical cancer

Therapies

Dostarlimab + Niraparib

Age Groups: adult senior

No variant requirements are available.